E-Rare 2015


E-Rare-3 Call for Proposals 2015 for “Transnational Research Projects on Rare Diseases”

Muscular Dystrophy Canada is pleased to announce that we have renewed our partnership with CIHR Institute of Genetics and will providing $300,000 towards successful applications in the 2015 “Transnational Research Projects on Rare Diseases” launched by E-Rare-3

The following parties have decided to open the seventh E-Rare joint transnational call (JTC 2015) for funding multilateral research projects on rare diseases together with the European Commission (EC) under the ERA-NET Co-fund mechanism.

  • Austrian Science Fund (FWF), Austria
  • Austrian Research Promotion Agency (FFG), Austria
  • Research Foundation Flanders (FWO), Belgium, Flanders
  • Fund for Scientific Research – FNRS (F.R.S.-FNRS), Belgium, French-speaking community
  • Canadian Institutes of Health Research – Institute of Genetics (CIHR-IG), Canada
  • Fonds de recherche du Québec-Santé (FRQS), Québec (Canada)
  • Genome Canada (GC), Canada
  • French National Research Agency (ANR), France
  • Federal Ministry of Education and Research (BMBF), Germany
  • German Research Foundation (DFG), Germany
  • General Secretariat for Research and Technology (GSRT), Greece
  • Hungarian Scientific Research Fund (OTKA), Hungary
  • Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel
  • Italian Ministry of Health (MoH), Italy
  • Regione Emilia-Romagna – Agenzia Sanitaria e Sociale Regionale (RER-ASSR), Italy
  • Latvian Academy of Sciences (LAS), Latvia
  • National Centre for Research and Development (NCBR), Poland
  • Foundation for Science and Technology (FCT), Portugal
  • Executive Agency for Higher Education, Research, Development and Innovation Funding (UEFISCDI), Romania
  • National Institute of Health Carlos III (ISCIII), Spain
  • Swiss National Science Foundation (SNSF), Switzerland
  • Netherlands Organization for Health Research and Development (ZonMw), The Netherlands
  • Scientific and Technological Research Council of Turkey (TÜBITAK), Turkey


The aim of the call is to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on sharing of expertise, with a clear translational research approach. Projects shall involve a group of rare diseases or a single rare disease following the European definition i.e. a disease affecting not more than five in 10,000 persons in the European Community.

The call is in compliance with the goals set by the International Rare Diseases Research Consortium (IRDiRC) which fosters international collaboration in rare diseases research. For more information see IRDiRC website: irdirc.org


Transnational research proposals must cover at least one of the following areas, which are equal in relevance for this call:

  1. Collaborative research using patient databases and corresponding collections of biological material that would generally not be possible at a national scale. This research must have clear potential for clinical application and well defined scientific objectives e.g.:
    • definition of new nosological entities, epidemiological studies, genotype/phenotype correlations, natural history of diseases;
    • characterisation of the genetic/molecular basis of specific diseases
  2. Research on rare diseases including genetic, epigenetic, and pathophysiological studies, using innovative and shared resources, technologies (OMICS, new generation sequencing, etc.) and expertise.
  3. Research on development of applications for diagnosis and therapies for rare diseases. This may include identification and characterisation of (bio)-markers for diagnosis and prognosis, development of innovative screening systems and diagnostic tools, the generation of relevant cellular and/or animal models, and preclinical studies using pharmacological, gene or cell therapies.

Project proposals must clearly demonstrate the potential health impact as well as the added-value of transnational collaboration: gathering a critical mass of patients/biological material, sharing of resources (models, databases, diagnosis etc.), harmonisation of data, sharing of specific know-how and/or innovative technologies, etc.

Each transnational collaborative project should represent the critical mass to achieve ambitious scientific goals. Consortia are encouraged to demonstrate engagement with industry for its active participation including areas of collaboration, sharing of resources, capabilities and expertise, in order to ensure an efficient transfer of pre-clinical results into clinical utility. Likewise, patient organizations are invited to participate where appropriate as their engagement has the potential to provide new insights that could lead to innovative discoveries, and ensures that research is relevant to patients’ concerns.

The following diseases/topics are excluded from the scope of the call:

  • Interventional clinical trials;
  • Rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases;
  • Rare neurodegenerative diseases which are within the focus of the Joint Programming Initiative on Neurodegenerative Disease Research (JPND; neurodegenerationresearch.eu). These concern: Alzheimer’s disease (AD) and other dementias; Parkinson’s disease (PD) and PD-related disorders; Prion disease; Motor neuron diseases (MND); Huntington’s Disease (HD); Spinal muscular atrophy (SMA) and dominant forms of Spinocerebellar ataxia (SCA). Interested researchers should refer to the relevant JPND calls.

Overview of Eligibility

Only transnational projects will be funded. Each consortium must involve a minimum of three and a maximum of six research groups from at least three different participating countries. See list above.

No more than two eligible partners from the same country participating in the call will be accepted in one consortium.

Consortia of projects funded in previous E-Rare joint transnational calls can apply for funding for an extension of their cooperation. These consortia must clearly demonstrate the success of the current project and innovative scientific aims for their future collaboration. Their applications will compete with applications for new research projects.

The duration of the projects can be up to 3 years. Nevertheless, a partner can receive funding for less than 3 years according to E-Rare-3 JTC 2015 funding organisations eligibility criteria and regulations.

For complete information regarding eligibility, see Guidelines for Applicants


There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals.

  • Opening of the call: December 15, 2014
  • Registration: January 2015. Research consortia who intend to submit a transnational project proposal should register at the electronic proposal system.
  • Deadline for pre-proposals submission: February 18, 2015. See “Guidelines for Applicants
  • Decision on selection of applications for invitation to full proposal: end of April 2015.
  • Deadline for full proposals: June 2, 2015
  • Anticipated notice of decision: October 30, 2015
  • Funding start date: April 1, 2016



Register your intent to apply.


Please note that full proposals will be accepted only from those applicants who were explicitly invited to submit them.

  • Canadian applicants invited to submit a Full Application to the Joint Transnational Call must complete a CIHR application and submit it using ResearchNet. See details
  • The deadline for submission of this application is June 2, 2015.
Questions? Please contact:

Marla Spiegel

National Director, Research, Programs and Services
 Muscular Dystrophy Canada

2345 Yonge Street, Suite 900
 Toronto ON M4P 2E5

Telephone: 1-866-687-2538 ext 1103

Marilyn Desrosiers
Deputy Director, Strategic Program Design and Analytics
Telephone: 613-954-6242
Email: marilyn.desrosiers@cihr-irsc.gc.ca

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann